922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models

• Zoe Johnson,
• Alan Carruthers,
• Elisa Matas-Rico,
• Marcel Deken,
• Karolina Niewola,
• Ragini Medhi,
• Anne Cheasty,
• Olivier Peyruchaud,
• Amy Fraser,
• Pritom Shah,
• Wouter Moolenaar,
• Lars van der Veen,
• Michael Lahn

Affiliations

Zoe Johnson

Department of Ophthalmology, Aberdeen, UK

Alan Carruthers

3 Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

Elisa Matas-Rico

Genitourinary Cancer Translational Research Group, Instituto de Investigación Biomédica de Málaga, Málaga, Spain

Marcel Deken

1IONCTURA SA, Genève, Switzerland

Karolina Niewola

1IONCTURA SA, Genève, Switzerland

Ragini Medhi

3CRUK-TDL, Cambridge, UK

Anne Cheasty

3CRUK-TDL, Cambridge, UK

Olivier Peyruchaud

4INSERM U1033, Lyon, France

Amy Fraser

3CRUK-TDL, Cambridge, UK

Pritom Shah

3CRUK-TDL, Cambridge, UK

Wouter Moolenaar

5NKI, Amsterdam, UK

Lars van der Veen

1IONCTURA SA, Genève, Switzerland

Michael Lahn

1IONCTURA SA, Genève, Switzerland